ERBB2 and adenocarcinoma: Median OS from start of first-linetherapy of patients with human epidermal growth factor receptor 2(HER2)-negative adenocarcinomas was 7.6, 7.8, and 7.5 months(p = 0.12) and of patients with HER2-positive carcinomareceiving first-line trastuzumab-containing therapy was 11.0, 13.3, and9.5 months (p = 0.37) in EAC, GEJC, and GAC, respectively.After multivariable adjustment, no difference in OS for patients with EAC,GEJC, and GAC was observed.